Navigation Links
Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
Date:7/22/2010

KING OF PRUSSIA, Pa., July 22 /PRNewswire/ -- Recovering unnecessarily lost patient information is now a viable reality.  Lost to follow up (L2FU) rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.

Consequently, regulatory agencies such as the FDA, are requesting that clinical trial sponsors perform comprehensive follow up measures as part of a clinical trial's due diligence efforts or during the conduct of long term safety surveillance studies to monitor patient outcomes.

L2FU, a company specializing in helping clinical trial sites and biopharma companies to locate, contact and collect data from patients deemed 'Lost to Follow-Up', is building a portfolio of successes and an industry reputation for its quality work. The L2FU team proudly reports its latest successful recovery of 100% of a recent study's lost clinical trial patients. This was achieved in only one month to meet a truncated timeline.  The client, a leading integrated managed care organization, with operations in a number of major states across the US and nearly 10 million patient members, required the information rapidly.

The L2FU team worked diligently to recover the lost patients, who were located in other states while acquiring new addresses. "Finding these lost patients several years after their clinical trial participation goes a long way to ensuring that our client's study meets its primary endpoints, and that all of their data is accepted by the Food and Drug Administration (FDA)," noted Bernard Hall, L2FU's manager and main point of contact.

L2FU works closely with clinical research sites and data managers at clinical research organizations (CROs) and biopharmaceutical companies to transmit collected patient data in a secure manner; adhering to HIPAA regulations for privacy and data security. The L2FU team is experienced in proactively recovering lost study subjects and sensitively communicating with patients and their families. Team members are trained on the procedures required for the licensed access to many databases containing millions of vital records.

Employing L2FU to manage lost patients allows already overworked study coordinators to focus their time on active patients in the study, and the L2FU team provides clinical trial sponsors the reassurance that missing patients and required outcome data will be accounted for.

L2FU is part of MediciGlobal, a global leader in the recruitment and retention of patients for clinical trials. With more than 20 years of clinical trials experience in patient recruitment-retention, MediciGlobal is a company dedicated to the recruitment-retention and reconnection of patients for clinical trials.  For more information on L2FU visit http://www.L2FU.com or call Bernard Hall at 484-674-6816.


'/>"/>
SOURCE MediciGlobal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
2. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
3. Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
4. Medical Device Consultants, Inc. and Clinical Development & Support Services Ltd Announce Strategic Partnership
5. Innovative Partnership Helps Improve Medical Research by Optimizing Clinical Trials
6. Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need
7. Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimers Disease at International Conference on Alzheimers Disease (ICAD)
8. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
9. ISTA Pharmaceuticals Initiates Clinical Development of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
10. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
11. Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimers Association International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - 2019" ... North America continued to lead global anti-bacterial ... into revenues worth US$ 16,907.3 million. North ... , Latin America , Middle-East ... market is inclined towards North America and ...
(Date:2/9/2016)... BETHESDA, Md. , Feb. 9, 2016 /PRNewswire-USNewswire/ ... community for pharmaceutical professionals developing and manufacturing sterile ... Global Sterile Manufacturing Regulatory Guidance Comparison – With ... regulatory guidance documents issued by the U.S. FDA, ... World Health Organization. --> ...
(Date:2/8/2016)... Feb.8, 2016 Alzheimer Diagnostic Tests - ... Medical Devices sector report , "Alzheimer Diagnostic ... an overview of Alzheimer Diagnostic Tests currently in ... on the pipeline products with comparative analysis of ... report reviews major players involved in the pipeline ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its ... cancer. , Gary D. Radine, who recently retired as president and CEO of Delta ... 2015 CEO of the Year , helped lead the effort to raise funds ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating ... a significant number of women and men with eating disorders report a history ... best predicts the development of an eating disorder. , At the 2016 ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific ... can use newly released government data on populations and physicians to better calculate ... capture the value they create to succeed in new economic models for value ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... only four states in the U.S. require dental technicians to be certified or ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
Breaking Medicine News(10 mins):